A Study of LY3532226 in Participants With Obesity

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Obesity

Interventions

DRUG

LY3532226

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (4)

Fortrea Clinical Research Unit, Daytona Beach

Fortrea Clinical Research Unit, Madison

Fortrea Clinical Research Unit, Dallas

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06557356 - A Study of LY3532226 in Participants With Obesity | Biotech Hunter | Biotech Hunter